Stereotaxis (STXS) Income from Continuing Operations (2010 - 2026)
Stereotaxis (STXS) posted quarterly Income from Continuing Operations of 12778000.0 for Q1 2026, down 105.34% year-over-year from 239510524.1 in Q1 2025, and down 83.49% quarter-over-quarter from 6964000.0 in Q4 2025.
Stereotaxis (STXS) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has reported Income from Continuing Operations for 17 consecutive years, with 12778000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 105.34% year-over-year to 12778000.0; the TTM figure through Mar 2026 stood at 32458000.0 (down 16.93% YoY), while the FY2025 annual figure was 24312000.0, up 61.77% from the prior year.
- Income from Continuing Operations declined to 12778000.0 in Q1 2026 per STXS's latest filing, from 6964000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4523000.0 in Q1 2022 and bottomed at 12778000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 6350705.88 across 5 years, with a median of 5861000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 109.5% — and 2025, when it climbed 19.3%.
- Stereotaxis' Income from Continuing Operations stood at 4696000.0 in 2022, then declined by 18.46% to 5563000.0 in 2023, then slumped by 55.13% to 8630000.0 in 2024, then advanced by 19.3% to 6964000.0 in 2025, then plunged by 83.49% to 12778000.0 in 2026.
- Business Quant data shows STXS's Income from Continuing Operations at 12778000.0 in Q1 2026, 6964000.0 in Q4 2025, and 6855000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 823.20 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 452.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 383.43 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 139.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 93.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -77.90 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 135.00 Mn |
| 10 | Stereotaxis | 141.91 Mn | 127.29 Mn | 3.79 Mn | -5.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.78 Mn |
| Dec 31, 2025 | -6.96 Mn |
| Sep 30, 2025 | -6.86 Mn |
| Jun 30, 2025 | -5.86 Mn |
| Mar 31, 2025 | -6.22 Mn |
| Dec 31, 2024 | -8.63 Mn |
| Sep 30, 2024 | -6.63 Mn |
| Jun 30, 2024 | -6.27 Mn |
| Mar 31, 2024 | -5.00 Mn |
| Dec 31, 2023 | -5.56 Mn |
| Sep 30, 2023 | -5.89 Mn |
| Jun 30, 2023 | -5.52 Mn |
| Mar 31, 2023 | -5.86 Mn |
| Dec 31, 2022 | -4.70 Mn |
| Sep 30, 2022 | -5.28 Mn |
| Jun 30, 2022 | -5.40 Mn |
| Mar 31, 2022 | -4.52 Mn |
| Dec 31, 2021 | -3.78 Mn |
| Sep 30, 2021 | -5.24 Mn |
| Jun 30, 2021 | -3.93 Mn |